首頁 > 市場調查報告書 > 製藥

癌症生物標記

市場調查報告書

商品編碼

1905118

日本癌症生物標記市場報告（按分析技術、生物分子、癌症類型、應用、最終用戶和地區分類，2026-2034）

Japan Cancer Biomarkers Market Report by Profiling Technology, Biomolecule, Cancer Type, Application, End User, and Region 2026-2034

出版日期: 2026年01月01日 | 出版商:

IMARC | 英文 120 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2025年，日本癌症生物標記市場規模達13.929億美元。展望未來， IMARC Group預計到2034年，該市場規模將達到36.36億美元，2026年至2034年間的複合年成長率（CAGR）為11.25%。癌症病例的不斷增加，以及對有效診斷和監測工具日益成長的需求（這些工具能夠顯著提高治療成功率和改善患者預後），是推動市場成長的主要因素。

本報告解答的關鍵問題：

日本癌症生物標記市場目前表現如何？未來幾年又將如何發展？
新冠疫情對日本癌症生物標記市場產生了哪些影響？
日本癌症生物標記市場依分析技術分類的組成是怎樣的？
日本癌症生物標記市場依生物分子類型分類的組成是怎樣的？
日本癌症生物標記市場按癌症類型分類的組成是怎樣的？
日本癌症生物標記市場按應用領域分類的組成是怎樣的？
日本癌症生物標記市場以最終用戶分類的組成是怎樣的？
日本癌症生物標記市場價值鏈的各個階段有哪些？
日本癌症生物標記研究的關鍵促進因素和挑戰是什麼？
日本癌症生物標記市場的結構是怎麼樣的？主要參與者有哪些？
日本癌症生物標記市場的競爭程度如何？

Japan cancer biomarkers market size reached USD 1,392.9 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 3,636.0 Million by 2034, exhibiting a growth rate (CAGR) of 11.25% during 2026-2034. The increasing cases of cancer, coupled with the rising need for effective diagnostic and monitoring tools to significantly improve the chances of successful treatment and better patient outcomes, are driving the market.

Cancer biomarkers are molecules or substances found in the body that can indicate the presence of cancer or provide information about its characteristics. These biomarkers are typically detected through blood tests, tissue samples, or imaging studies. They play a crucial role in cancer diagnosis, prognosis, and treatment. Biomarkers can include proteins, genes, hormones, or even specific cellular changes. By analyzing their levels or activity, healthcare professionals can identify the type of cancer, its stage, and its potential aggressiveness. This information helps in tailoring treatment plans, monitoring disease progression, and assessing treatment effectiveness. Cancer biomarkers also have a significant impact on personalized medicine, enabling doctors to choose the most appropriate therapies for individual patients. Additionally, they aid in cancer research, facilitating the development of new drugs and therapies. Overall, cancer biomarkers are essential tools in the fight against cancer, contributing to early detection, precise treatment, and improved patient outcomes.

Japan Cancer Biomarkers Market Trends:

The cancer biomarkers market in Japan is driven by several key factors that collectively contribute to its growth and significance in the field of oncology. Firstly, advancements in molecular biology and genomics have paved the way for the identification of novel biomarkers that can aid in early cancer detection and prognosis. Moreover, the increasing prevalence of cancer in Japan is a major driver, as there is a growing need for accurate and efficient diagnostic tools to combat this regional health challenge. Furthermore, the development of targeted therapies and personalized medicine approaches has accentuated the demand for biomarkers. These biomarkers assist in tailoring treatment plans to individual patients, improving the overall efficacy of cancer treatments while minimizing adverse effects. Additionally, the rise in R&D activities in the pharmaceutical and biotechnology sectors has spurred investments in biomarker discovery and validation, further propelling market growth. Moreover, the widespread adoption of liquid biopsy techniques for non-invasive biomarker detection, as they offer a less invasive alternative to traditional tissue biopsies, is expected to drive the cancer biomarkers market in Japan during the forecast period.

Japan Cancer Biomarkers Market Segmentation:

Profiling Technology Insights:

Omic Technologies
Imaging Technologies
Immunoassays
Cytogenetics

Biomolecule Insights:

Genetic Biomarkers
Protein Biomarkers
Glyco-Biomarkers

Cancer Type Insights:

Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Stomach Cancer
Others

Application Insights:

Diagnostics
Prognostics
Risk Assessment
Drug Discovery and Development
Others

End User Insights:

Hospitals
Academic and Research Institutions
Ambulatory Surgical Centers
Diagnostic Laboratories
Others

Regional Insights:

Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan cancer biomarkers market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan cancer biomarkers market?
What is the breakup of the Japan cancer biomarkers market on the basis of profiling technology?
What is the breakup of the Japan cancer biomarkers market on the basis of biomolecule?
What is the breakup of the Japan cancer biomarkers market on the basis of cancer type?
What is the breakup of the Japan cancer biomarkers market on the basis of application?
What is the breakup of the Japan cancer biomarkers market on the basis of end user?
What are the various stages in the value chain of the Japan cancer biomarkers market?
What are the key driving factors and challenges in the Japan cancer biomarkers?
What is the structure of the Japan cancer biomarkers market and who are the key players?
What is the degree of competition in the Japan cancer biomarkers market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Cancer Biomarkers Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Cancer Biomarkers Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Cancer Biomarkers Market - Breakup by Profiling Technology

6.1 Omic Technologies
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Forecast (2026-2034)
6.2 Imaging Technologies
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Forecast (2026-2034)
6.3 Immunoassays
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2020-2025)
- 6.3.3 Market Forecast (2026-2034)
6.4 Cytogenetics
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2020-2025)
- 6.4.3 Market Forecast (2026-2034)

7 Japan Cancer Biomarkers Market - Breakup by Biomolecule

7.1 Genetic Biomarkers
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Forecast (2026-2034)
7.2 Protein Biomarkers
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Forecast (2026-2034)
7.3 Glyco-Biomarkers
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2020-2025)
- 7.3.3 Market Forecast (2026-2034)

8 Japan Cancer Biomarkers Market - Breakup by Cancer Type

8.1 Breast Cancer
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Forecast (2026-2034)
8.2 Lung Cancer
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Forecast (2026-2034)
8.3 Colorectal Cancer
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2020-2025)
- 8.3.3 Market Forecast (2026-2034)
8.4 Prostate Cancer
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2020-2025)
- 8.4.3 Market Forecast (2026-2034)
8.5 Stomach Cancer
- 8.5.1 Overview
- 8.5.2 Historical and Current Market Trends (2020-2025)
- 8.5.3 Market Forecast (2026-2034)
8.6 Others
- 8.6.1 Historical and Current Market Trends (2020-2025)
- 8.6.2 Market Forecast (2026-2034)

9 Japan Cancer Biomarkers Market - Breakup by Application

9.1 Diagnostics
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2020-2025)
- 9.1.3 Market Forecast (2026-2034)
9.2 Prognostics
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2020-2025)
- 9.2.3 Market Forecast (2026-2034)
9.3 Risk Assessment
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2020-2025)
- 9.3.3 Market Forecast (2026-2034)
9.4 Drug Discovery and Development
- 9.4.1 Overview
- 9.4.2 Historical and Current Market Trends (2020-2025)
- 9.4.3 Market Forecast (2026-2034)
9.5 Others
- 9.5.1 Historical and Current Market Trends (2020-2025)
- 9.5.2 Market Forecast (2026-2034)

10 Japan Cancer Biomarkers Market - Breakup by End User

10.1 Hospitals
- 10.1.1 Overview
- 10.1.2 Historical and Current Market Trends (2020-2025)
- 10.1.3 Market Forecast (2026-2034)
10.2 Academic and Research Institutions
- 10.2.1 Overview
- 10.2.2 Historical and Current Market Trends (2020-2025)
- 10.2.3 Market Forecast (2026-2034)
10.3 Ambulatory Surgical Centers
- 10.3.1 Overview
- 10.3.2 Historical and Current Market Trends (2020-2025)
- 10.3.3 Market Forecast (2026-2034)
10.4 Diagnostic Laboratories
- 10.4.1 Overview
- 10.4.2 Historical and Current Market Trends (2020-2025)
- 10.4.3 Market Forecast (2026-2034)
10.5 Others
- 10.5.1 Historical and Current Market Trends (2020-2025)
- 10.5.2 Market Forecast (2026-2034)

11 Japan Cancer Biomarkers Market - Breakup by Region

11.1 Kanto Region
- 11.1.1 Overview
- 11.1.2 Historical and Current Market Trends (2020-2025)
- 11.1.3 Market Breakup by Profiling Technology
- 11.1.4 Market Breakup by Biomolecule
- 11.1.5 Market Breakup by Cancer Type
- 11.1.6 Market Breakup by Service
- 11.1.7 Market Breakup by End User
- 11.1.8 Key Players
- 11.1.9 Market Forecast (2026-2034)
11.2 Kansai/Kinki Region
- 11.2.1 Overview
- 11.2.2 Historical and Current Market Trends (2020-2025)
- 11.2.3 Market Breakup by Profiling Technology
- 11.2.4 Market Breakup by Biomolecule
- 11.2.5 Market Breakup by Cancer Type
- 11.2.6 Market Breakup by Service
- 11.2.7 Market Breakup by End User
- 11.2.8 Key Players
- 11.2.9 Market Forecast (2026-2034)
11.3 Central/ Chubu Region
- 11.3.1 Overview
- 11.3.2 Historical and Current Market Trends (2020-2025)
- 11.3.3 Market Breakup by Profiling Technology
- 11.3.4 Market Breakup by Biomolecule
- 11.3.5 Market Breakup by Cancer Type
- 11.3.6 Market Breakup by Service
- 11.3.7 Market Breakup by End User
- 11.3.8 Key Players
- 11.3.9 Market Forecast (2026-2034)
11.4 Kyushu-Okinawa Region
- 11.4.1 Overview
- 11.4.2 Historical and Current Market Trends (2020-2025)
- 11.4.3 Market Breakup by Profiling Technology
- 11.4.4 Market Breakup by Biomolecule
- 11.4.5 Market Breakup by Cancer Type
- 11.4.6 Market Breakup by Service
- 11.4.7 Market Breakup by End User
- 11.4.8 Key Players
- 11.4.9 Market Forecast (2026-2034)
11.5 Tohoku Region
- 11.5.1 Overview
- 11.5.2 Historical and Current Market Trends (2020-2025)
- 11.5.3 Market Breakup by Profiling Technology
- 11.5.4 Market Breakup by Biomolecule
- 11.5.5 Market Breakup by Cancer Type
- 11.5.6 Market Breakup by Service
- 11.5.7 Market Breakup by End User
- 11.5.8 Key Players
- 11.5.9 Market Forecast (2026-2034)
11.6 Chugoku Region
- 11.6.1 Overview
- 11.6.2 Historical and Current Market Trends (2020-2025)
- 11.6.3 Market Breakup by Profiling Technology
- 11.6.4 Market Breakup by Biomolecule
- 11.6.5 Market Breakup by Cancer Type
- 11.6.6 Market Breakup by Service
- 11.6.7 Market Breakup by End User
- 11.6.8 Key Players
- 11.6.9 Market Forecast (2026-2034)
11.7 Hokkaido Region
- 11.7.1 Overview
- 11.7.2 Historical and Current Market Trends (2020-2025)
- 11.7.3 Market Breakup by Profiling Technology
- 11.7.4 Market Breakup by Biomolecule
- 11.7.5 Market Breakup by Cancer Type
- 11.7.6 Market Breakup by Service
- 11.7.7 Market Breakup by End User
- 11.7.8 Key Players
- 11.7.9 Market Forecast (2026-2034)
11.8 Shikoku Region
- 11.8.1 Overview
- 11.8.2 Historical and Current Market Trends (2020-2025)
- 11.8.3 Market Breakup by Profiling Technology
- 11.8.4 Market Breakup by Biomolecule
- 11.8.5 Market Breakup by Cancer Type
- 11.8.6 Market Breakup by Service
- 11.8.7 Market Breakup by End User
- 11.8.8 Key Players
- 11.8.9 Market Forecast (2026-2034)

12 Japan Cancer Biomarkers Market - Competitive Landscape

12.1 Overview
12.2 Market Structure
12.3 Market Player Positioning
12.4 Top Winning Strategies
12.5 Competitive Dashboard
12.6 Company Evaluation Quadrant

13 Profiles of Key Players

13.1 Company A
- 13.1.1 Business Overview
- 13.1.2 Product Portfolio
- 13.1.3 Business Strategies
- 13.1.4 SWOT Analysis
- 13.1.5 Major News and Events
13.2 Company B
- 13.2.1 Business Overview
- 13.2.2 Product Portfolio
- 13.2.3 Business Strategies
- 13.2.4 SWOT Analysis
- 13.2.5 Major News and Events
13.3 Company C
- 13.3.1 Business Overview
- 13.3.2 Product Portfolio
- 13.3.3 Business Strategies
- 13.3.4 SWOT Analysis
- 13.3.5 Major News and Events
13.4 Company D
- 13.4.1 Business Overview
- 13.4.2 Product Portfolio
- 13.4.3 Business Strategies
- 13.4.4 SWOT Analysis
- 13.4.5 Major News and Events
13.5 Company E
- 13.5.1 Business Overview
- 13.5.2 Product Portfolio
- 13.5.3 Business Strategies
- 13.5.4 SWOT Analysis
- 13.5.5 Major News and Events

14 Japan Cancer Biomarkers Market - Industry Analysis

14.1 Drivers, Restraints, and Opportunities
- 14.1.1 Overview
- 14.1.2 Drivers
- 14.1.3 Restraints
- 14.1.4 Opportunities
14.2 Porters Five Forces Analysis
- 14.2.1 Overview
- 14.2.2 Bargaining Power of Buyers
- 14.2.3 Bargaining Power of Suppliers
- 14.2.4 Degree of Competition
- 14.2.5 Threat of New Entrants
- 14.2.6 Threat of Substitutes
14.3 Value Chain Analysis